Thank you for Subscribing to Life Science Review Weekly Brief
Nominate a Company
Our subscribers nominate the companies with whom they have collaborated and gotten results. If you think there is a company that deserves to be on our upcoming prestigious annual list of Top HealthcareBuisness companies, please write to us about them and the reasons you think they need to be on the list
×
Healthcare Business Review Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Healthcare Business Review
Curebase Chooses Amendola Communications for Strategic Public Relations and Social Media Services
Healthcare Business Review | Tuesday, August 24, 2021
Curebase is developing a new approach to the entire clinical trial process with a distinct DCT model that revolves around the patient's lifestyle, allowing for diverse studies with larger patient populations.
Fremont, CA: Amendola Communications, a nationally recognized, award-winning healthcare and technology public relations and marketing firm, has declared that Curebase, a company committed to democratizing access to clinical studies, has chosen the agency to launch a comprehensive media and communications program highlighting its innovative Decentralized Clinical Trial (DCT) software platform and work to make clinical trials not only more patient-centric but also faster and more cost-efficient. The decision was taken after an extensive review of other national agencies.
Curebase is developing a new approach to the entire clinical trial process with a distinct DCT model that revolves around the patient's lifestyle, allowing for diverse studies with larger patient populations. The Curebase platform enables sponsors, CROs, and physicians to conduct first-of-its-kind study designs in which patients participate both at home and in real-world settings using best-in-class software.
"We are excited to leverage Amendola, which brings a stealthy team, strategic healthcare IT expertise, and a long history of proven wins," stated Tom Lemberg, founder and CEO of Curebase. "We are proud to have helped many companies rapidly complete their clinical research, including those who achieved emergency use authorization during the pandemic. Our vision is to make clinical research an option for all patients, regardless of their care setting, and we are certain the Amendola team will be terrific partners in these efforts."
"We look forward to the opportunity to help bring Curebase's vision for a democratized clinical research industry to life," stated agency CEO Jodi Amendola. "They are a fast-rising powerhouse in the DCT space—developing innovative approaches for their clients and redefining how the world executes healthcare research. Curebase is building a future that includes better diversity, quicker enrollment, and improved patient satisfaction for all clinical trials."
